MAP2 and neuroblastoma: We found that both EZRIN and MAP2 higher expression levels were significantly associated with higher event-free and overall survival rates in NB patients (Fig 1A and 1B), which suggested a role of these molecules together with CHL1, in leading to a more favorable NB outcome by inducing cell differentiation.